Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. Èììóíîöèòîòåðàïèÿ ïðè NLA íåñîâìåñòèìîñòè (ïðè íåâûíàøèâàíèè áåðåìåííîñòè)
    îò s-klass â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 9
    : 24.01.2007, 21:19
  2. íåïðàâèëüíîå ââåäåíèå ïàíàâèðà
    îò miraba â ðàçäåëå Âåíåðîëîã-äåðìàòîëîã
    Îòâåòîâ: 15
    : 22.11.2006, 21:34
  3. ââåäåíèå ãëþòåíîâûõ êàø
    îò Þëèÿ â ðàçäåëå Ïåäèàòð - âñå î äåòÿõ.
    Îòâåòîâ: 1
    : 01.08.2005, 14:37
  4. Ââåäåíèå èìóíîãëîáóëèíîâ ïðè íåâûíàøèâàíèè
    îò î.îõîòà â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 7
    : 01.09.2004, 19:30
  5. ïðàâèëüíî ââåäåíèå âëàãàëèù. òàìïîíîâ
    îò faradada â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 1
    : 31.08.2004, 17:19
  1. î.îõîòà
    #1
    ×èòàòåëü Íåäóã.Ðó
    Çäðàâñòâóéòå!

    Ïîçàäè 2 çàìåðøèå. Èíôåêöèè, ãîðìîíû, óçè - âñå â íîðìå.

    Âûÿâëåíî ïîâûøåíèå ÍÊ-êëåòîê â èììóíîãðàììå. Íàçíà÷èëè èììóíîãëîáóëèíû ïðè ïëàíèðîâàíèè áåðåìåííîñòè. Êàê îêàçàëîñü, ýòà èììóíîãðàììà ñäàâàëàñü íà ôîíå óðåàïëàçìû. Ïîñëå ëå÷åíèÿ óðåàïëàçìû ïåðåñäàëà èììóíîãðàììó - âñå ïîêàçàòåëè â íîðìå. Íî åñòü áîëüøèå îòêëîíåíèÿ â èíòåðôåðîíîâîì ñòàòóñå:

    >ÈÔÍ â ñûâîðîòêå êðîâè - 8 (íîðìà <4)

    ñïîíòàííàÿ ðåàêöèÿ <4 (N. <4)

    âèðóñ èíäóöèðîâàííàÿ (ÈÔÍ-à) - 4-8 (N. 64-256)

    ìèòîãåí-èíäóöèðîâàííàÿ ÔÃÀ (ÈÔÍ-ó) - 8 (N. 16-64).

    ×óâñòâèòåëüíîñòü ê ãàëàâèòó, ëèêîïèäó, èììóíîìàêñó.

    Ïîêàçàí ëè ìíå ïðèåì èììóíîãëîáóëèíîâ, èëè ìîæíî îãðàíè÷èòüñÿ ýòèìè ïðåïàðàòàìè? Âîçìîæíî ëè ñî÷åòàíèå èììóíîãëîáóëèíîâ è ýòèõ ïðåïàðàòîâ? Èëè îíè èñêëþ÷àþò äðóã äðóãà? ×òî èç íèõ ÿâëÿåòñÿ áîëåå ñèëüíûì âìåøàòåëüñòâîì â èììóíèòåò? Åñòü ëè ïîáî÷íûå ýôôåêòû ó èììóíîãëîáóëèíîâ?

    Áóäó ïðèçíàòåëüíà çà îòâåò

  2. Îlga
    #2
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìàÿ Amys!



    Ïðè íàëè÷èè ïðèâû÷íîé íåâûíàøèâàåìîñòè â ïåðâîé ïîëîâèíå áåðåìåííîñòè ïðè îòñóòñòâèè àíàòîìè÷åñêèõ è ãîðìîíàëüíûõ ïðîáëåì íàèáîëåå ÷àñòîé ïðè÷èíîé íåâûíàøèâàíèÿ ÿâëÿþòñÿ òðîìáîôèëèè - âðîæäåííûå èëè ïðèîáðåòåííûå äåôåêòû ñâåðòûâàíèÿ êðîâè, ïðèâîäÿùèå ê òðîìáèðîâàíèþ ïëàöåíòû. Ïîäðîáíåå ìîæåòå âçãëÿíóòü íà äèñêóññèè:



    http://forums./showthread.php?t=11791



    Íàðóøåíèÿ èììóíèòåòà òàêæå ìîãóò áûòü ïðè÷èíîé, íî â ìåíüøåì % ñëó÷àåâ è òðåáóåò ïðîâåäåíèÿ ñïåöèôè÷åñêèõ òåñòîâ.



    Î èììóíîãëîáóëèíå(IVIG): ñóùåñòâóåò íåäàâíèé êîíñåíñóñ, ãäå ãîâîðèòñÿ ñëåäóþùåå:



    The effectiveness of IVIG as a treatment for recurrent spontaneous pregnancy loss remains unproven. IVIG does not prevent further losses among women with primary recurrent spontaneous pregnancy loss. A potential effect has been demonstrated in the less prevalent problem of secondary recurrent spontaneous pregnancy loss. The published data are insufficient, however, to exclude the possibility that the treatment also has no value in the latter condition.



    Ýôôåêòèâíîñòü íåäîêàçàíà, ïðè ïåðâè÷íûõ íåâûíàøèâàíèÿõ áåñïîëåçåí, ïðè âòîðè÷íûõ - ìîæåò áûòü, íî ñâèäåòåëüñòâî ñëàáîâàòîå.



    Ïîáî÷íûå ýôôåêòû:



    Severe side effects of IVIG are rare in well-selected patients. Mild side effects including fever, malaise, myalgia and headache occur in 4% of patients. Severe reactions are encountered in IgA deficient patients; the prevalence of IgA deficiency is 1 per 1000. Nephrotoxicity, alopecia, aseptic meningitis and retinal necrosis are rare but serious side-effects.



    Èç Fertil Steril. 2004 Sep;82 Suppl 1:S199-200.

    Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss.

    Practice Committee of the American Society for Reproductive Medicine.



    Ïîýòîìó åãî èñïîëüçóþò, êîãäà äð. áîëåå ýôôåêòèâíûå ìåòîäû "íå ðàáîòàþò":



    ...intravenous immunoglobulin therapy appears to be reserved for very high risk pregnancies that have failed using heparin and aspirin...



    Èç Benson EM. Immunologic manipulation for the threatened fetus.

    Thromb Res. 2004;114(5-6):427-34



    "÷óâñòâèòåëüíûå ìîäóëÿòîðû" âîîáùå íèêòî íå èñïîëüçóåò (ìîæåò áûòü íåáåçîïàñíî äëÿ ìàòåðè è ïëîäà; íå îáÿçàòåëüíî, ÷òî èíâèòðî ýôôåêò áóäåò àíàëîãè÷åí èíâèâî).

  3. 555
    #3
    ×èòàòåëü Íåäóã.Ðó
    Ñïàñèáî çà îòâåò!

    Èç âàøåãî îòâåòà íå ïîíÿòåí îäèí ïóíêò:



    "÷óâñòâèòåëüíûå ìîäóëÿòîðû" âîîáùå íèêòî íå èñïîëüçóåò (ìîæåò áûòü íåáåçîïàñíî äëÿ ìàòåðè è ïëîäà; íå îáÿçàòåëüíî, ÷òî èíâèòðî ýôôåêò áóäåò àíàëîãè÷åí èíâèâî).[/QUOTE]



    ×òî òàêîå "÷óâñòâèòåëüíûå ìîäóëÿòîðû"?

    Èìåþòñÿ â âèäó èììóíîìîäóëÿòîðû (â òîì ÷èñëå íàçíà÷åííûé ìíå ãàëàâèò), èëè ÿ îøèáàþñü?



    Äà, õîòåëîñü áû óòî÷íèòü, ïåðâàÿ çàìåðøàÿ áûëà íà 15-16 íåäåëå (îáíàðóæåíî â 18 íåäåëü), âòîðàÿ - 4-5 íåä.



    Êðîìå èììóíîãëîáóëèíîâ, ìíå íàçíà÷åíà èììóíèçàöèÿ ëèìôîöèòàìè äîíîðà (íà îñíîâå ñîâïàäåíèÿ ïî 2ì ëîêóñàì HLA è ñëàáîãî ðàñïîçíàâàíèÿ ïî ÑÊË). Íàñêîëüêî äàííûå ñîâïàäåíèÿ ïîääàþòñÿ êàêîé-ëèáî êîððåêöèè? ß ÷èòàëà, ÷òî èììóíèçàöèÿ ïðèçíàåòñÿ äàëåêî íå âñåìè ñïåöèàëèñòàìè êàê ýôôåêòèâíîå ñðåäñòâî. Ïðåäëàãàåòñÿ ëè ÷òî-íèáóäü â êà÷åñòâå àëüòåðíàòèâû?

  4. Êýò
    #4
    ×èòàòåëü Íåäóã.Ðó
    Ôðàãìåíò èíñòðóêöèè èììóíîìàêñà:



    "Íå èìååòñÿ äàííûõ î âîçäåéñòâèè Èììóíîìàêñà íà áåðåìåííûõ æåíùèí. Êàê è â ñëó÷àå äðóãèõ ëåêàðñòâåííûõ ñðåäñòâ, Èììóíîìàêñ íå ñëåäóåò ïðèìåíÿòü âî âðåìÿ áåðåìåííîñòè, åñëè òîëüêî ïðåèìóùåñòâà, ïîëó÷àåìûå áîëüíîé, íå ïðåâûøàþò âîçìîæíûé ðèñê äëÿ ïëîäà."



    Ïî äðóãèì "ìîäóëÿòîðàì" ïîñìîòðèòå ñàìè â ñåòè, èáî "íîðìàëüíûõ èñòî÷íèêîâ" èõ áåçîïàñíîñòè, äóìàþ, íå ñóùåñòâóåò.

    Ñ äðóãîé ñòîðîíû, åñëè íàïð. ìîäóëÿòîð-òàêè (â ÷åì ãëóáîêî ñîìíåâàþñü) ïîìîæåò Âàì äîíîñèòü áåðåìåííîñòü, íî îáëàäàåò òåðàòîãåííûìè ñâîéñòâàìè, òî çà÷åì òàêîé ðåáåíîê (ñ âðîæäåííûìè óðîäñòâàìè)?



    Öèòàòà "ìíå íàçíà÷åíà èììóíèçàöèÿ ëèìôîöèòàìè äîíîðà (íà îñíîâå ñîâïàäåíèÿ ïî 2ì ëîêóñàì HLA è ñëàáîãî ðàñïîçíàâàíèÿ ïî ÑÊË)."



    Îòâåò: åñëè òîëüêî ðåáåíêà áóäåòå "çàâîäèòü" îò ýòîãî ñàìîãî äîíîðà. Âåäü, "ñîâïàäåíèå" è "ñëàáîå ðàñïîçíàâàíèå" âûÿâëåíî ó Âàñ ñ ïîòåíöèàëüíûì îòöîì ðåáåíêà, à íå ñ êàêèì-òî äîíîðîì?  íåäàâíåì àìåðèêàíñêîì èññëåäîâàíèè (ãäå-òî óæå ïðèâîäèë ññûëêó - ïîñìîòðèòå ïåðåïèñêó ñ YBLOKO) ïðè òàêèõ íàðóøåíèÿõ èììóíèçàöèÿ ëèìôîöèòàìè äîíîðà ïî ýôôåêòèâíîñòè ðàâíÿëàñü èììóíèçàöèè ñòåðèëüíîé âîäîé, òîãäà êàê èíäèâ. ÏÐÀÂÈËüÍÎ ïðèãîòîâëåííàÿ âàêöèíà îò îòöà îêàçûâàëà áîëüøèé ïîëîæèòåëüíûé ýôôåêò íà âûíàøèâàíèå.

  5. October
    #5
    ×èòàòåëü Íåäóã.Ðó
    Ñïàñèáî! âñå èíñòðóêöèè ê èììóíîìîäóëÿòîðàì äåéñòâèòåëüíî íå ñîîáùàþò î äåéñòâèè íà ðåáåíêà è î âëèÿíèè íà âûíàøèâàíèå.



    Âîîáùå, èììóíîìîäóëÿòîðû+èììóíèçàöèÿ+èììóíîãëîáóëèí = íå ñëèøêîì ëè âåëèêà íàãðóçêà íà èììóíèòåò, ñ êîòîðûì êàê èçâåñòíî øóòêè ïëîõè?

    Âîçìîæíî ëè, ÷òî áîëåå âåðîÿòíàÿ ïðè÷èíà çàìåðøåé íà ñòîëü ïîçäíåì ñðîêå áåðåìåííîñòè - íå èììóíîëîãèÿ (îíà âåäü â îñíîâíîì íà ðàííèõ ñðîêàõ âëèÿåò), à ñêàæåì ÀÔÑ (ìóòàöèè MTHFR, IL1R è TNFa èìåþòñÿ, ÀÒ ê êàðäèîëèïèíó è íàòèâíîé ÄÍÊ ñëàáî ïîëîæèòåëüíû)?

    Óäèâëÿåò òî, ÷òî âðà÷ ñêîíöåíòðèðîâàë âíèìàíèå íà èììóíîëîãèè, â òî âðåìÿ êàê ÀÔÑ ÿâëÿåòñÿ äåéñòâèòåëüíî äîêàçàííîé ïðè÷èíîé íåâûíàøèâàíèÿ áåðåìåííîñòåé íà ïîçäíèõ ñðîêàõ, à èììóíîëîãèÿ - ëèøü èëëþçîðíîé. Èëè ïðîïèñàííîå ëå÷åíèå âëèÿåò è íà ÀÔÑ?

  6. Ñìèðèê
    #6
    ×èòàòåëü Íåäóã.Ðó
    Äëÿ íà÷àëà íóæíî îïðåäåëèòüñÿ, êàêàÿ æå ïàòîëîãèÿ ó Âàñ äîìèíèðóåò - åñëè ÀÔËÑ, òî äîëæíû áûòü ÷åòêèå êðèòåðèè - îïðåäåëåí âîë÷. àíòèêîàãóëÿíò èëè àíòèòåëà ê êàðäèîëèïèíó â ñðåäíåì èëè âûñîêîì òèòðå è ýôôåêòèâíûì ÿâëÿåòñÿ àñïèðèí+íèçêîìîëåê.ãåïàðèí. Åñëè MTHFR è ãèïåðãîìîöèñòåèíåìèÿ, òî ýòî íåïëîõî êîððèãèðóåòñÿ ôîëèåâîé+êîáàëàìèí+ïèðèäîêñèí, åñëè äð. âèä òðîìáîôèëèè - òî òîëüêî íèçêîìîë. ãåïàðèí.  ýòèõ ñëó÷àÿõ íè ìîäóëÿòîðû, íè, âîáåíçèíû íè èììóíîãëîáóëèíû íå íóæíû. Î IL1R è TNFa êàê ïðè÷èíàõ ïðèâû÷íîãî âûêèäûøà íîðìàëüíîé ìåä. íàóêå íè÷åãî íå èçâåñòíî.



    Åùå ïðèìåð:



    All women with a thrombophilia were treated with low-dose aspirin plus low molecular weight heparin. All women with previously diagnosed HHC and/or MTHFR polymorphisms were treated with folate and vitamin B(6) and B(12) supplementation. In the thrombophilia group, 27 women conceived resulting in 20 successful pregnancies (74.1%) and 7 pregnancy losses (2 trisomy 16, 1 ectopic pregnancy and 4 unexplained miscarriages), i.e. an unexplained pregnancy loss rate of 14.8%. In the HHC/MTHFR group 22 women conceived, resulting in 17 successful pregnancies (77.3%) and 5 pregnancy losses (1 trisomy 16, 1 Turner syndrome and 3 unexplained miscarriages), i.e. an unexplained pregnancy loss rate of 13.6%.



    Gynecol Obstet Invest. 2004;57(3):127-31.

    Pregnancy outcome in patients with a history of recurrent spontaneous miscarriages and documented thrombophilias.

    Krabbendam I, Dekker GA.



    Åñëè óæ ñîâñåì áóäåò òóãî ñ äèàãíîçîì, òî áîëåå ïðàãìàòè÷íî íàçíà÷èòü âèò. ãðóïïû Â, ïëþñ àñïèðèí 50-75 ìã ïëþñ íèçêîìîëåêóëÿðíûé ãåïàðèí íà âñþ áåðåìåííîñòü (ýôôåêòèâíîñòü äåòîðîæäåíèÿ 75-90%), ÷åì ýêñïåðèìåíòèðîâàòü ñ èììóíîãëîáóëèíàìè+ìèäóëÿòîðàìè+äîíîðñê.èììóíèçàöèå é. Ãëàâíîå - íàéòè âðà÷à, êîòîðûé áû Âàñ âåë íà ýòîì.

  7. tony19@yandex
    #7
    ×èòàòåëü Íåäóã.Ðó
    Çäðàâñòâóéòå! Î÷åíü ïðîøó ïðîêîíñóëüòèðîâàòü ìåíÿ!

    Ìíå 27 ëåò. Ó ìåíÿ áûëà îäíà áåðåìåííîñòü, çàêîí÷èâøàÿñÿ âûêèäûøåì íà ñðîêå 6 íåä, íà ñðîêå 2 íåä ÿ ïåðåíåñëà ãðèïï. ×åðåç 2 ìåñ ïîñëå ÷èñòêè ÿ ïðîøëà îáñëåäîâàíèå íà âûÿñíåíèå ïðè÷èí íåâûíàøèâàíèÿ. Áûëè îáíàðóæåíû ïîâûøåííûå óðîâíè ÀÒ ê ôîñôàòèäèëñåðèíó (IgM) è êàðäèîëèïèíó (òîæå IgM)è 17-ÎÍ. Åùå ÷åðåç 5 ìåñ ÿ ñäàëà àíàëèç êðîâè íà ñóììàðíûå ÀÒ ê ôîñôîëèïèäàì, ðåçóëüòàò - íîðìà.

    Ñåé÷àñ ÿ ïëàíèðóþ áåðåìåííîñòü. Ìíå íàçíà÷èëè äåêñàìåòàçîí 1/2ò/ä, àñïèðèí 50 ìã/ä , ôîëèåâóþ ê-òó è â/â ââåäåíèå ïðåïàðàòà ãàìàìóí (ýòî èììóíîãëîáóëèí) íà 20é ä.ö.

    Ñêàæèòå, ïîæàëóéñòà, íàñêîëüêî èììóíîãëîáóëèí ìíå ïîêàçàí. Åñëè îí íóæåí, òî ïî êàêîé ñõåìå ïðîâîäèòñÿ ëå÷åíèå? Íóæåí ëè ìíå ãåïàðèí íà ñòàäèè ïëàíèðîâàíèÿ áåðåìåííîñòè? (îí ìíå íå íàçíà÷åí, íî êàê ÿ ïîíÿëà, ãåïàðèí ïàòîãåíåòè÷åñêè íóæåí)

    Î÷åíü æäó îòâåòà!

    Ñïàñèáî!

  8. Äæàìáóë
    #8
    ×èòàòåëü Íåäóã.Ðó
    Çäðàâñòâóéòå! Î÷åíü ïðîøó ïðîêîíñóëüòèðîâàòü ìåíÿ!

    Ìíå 27 ëåò. Ó ìåíÿ áûëà îäíà áåðåìåííîñòü, çàêîí÷èâøàÿñÿ âûêèäûøåì íà ñðîêå 6 íåä, íà ñðîêå 2 íåä ÿ ïåðåíåñëà ãðèïï. ×åðåç 2 ìåñ ïîñëå ÷èñòêè ÿ ïðîøëà îáñëåäîâàíèå íà âûÿñíåíèå ïðè÷èí íåâûíàøèâàíèÿ. Áûëè îáíàðóæåíû ïîâûøåííûå óðîâíè ÀÒ ê ôîñôàòèäèëñåðèíó (IgM) è êàðäèîëèïèíó (òîæå IgM)è 17-ÎÍ. Åùå ÷åðåç 5 ìåñ ÿ ñäàëà àíàëèç êðîâè íà ñóììàðíûå ÀÒ ê ôîñôîëèïèäàì, ðåçóëüòàò - íîðìà.

    Ñåé÷àñ ÿ ïëàíèðóþ áåðåìåííîñòü. Ìíå íàçíà÷èëè äåêñàìåòàçîí 1/2ò/ä, àñïèðèí 50 ìã/ä , ôîëèåâóþ ê-òó è â/â ââåäåíèå ïðåïàðàòà ãàìàìóí (ýòî èììóíîãëîáóëèí) íà 20é ä.ö.

    Ñêàæèòå, ïîæàëóéñòà, íàñêîëüêî èììóíîãëîáóëèí ìíå ïîêàçàí. Åñëè îí íóæåí, òî ïî êàêîé ñõåìå ïðîâîäèòñÿ ëå÷åíèå? Íóæåí ëè ìíå ãåïàðèí íà ñòàäèè ïëàíèðîâàíèÿ áåðåìåííîñòè? (îí ìíå íå íàçíà÷åí, íî êàê ÿ ïîíÿëà, ãåïàðèí ïàòîãåíåòè÷åñêè íóæåí)

    Î÷åíü æäó îòâåòà!

    Ñïàñèáî!



    Ó Âàñ íåò ÀÔÑ. Èììóíîãëîáóëèí ÍÅ ïîêàçàí. Ñòàðàéòåñü ïîëüçîâàòüñÿ ïîèñêîì è çàäàâàòü âîïðîñû ïî ÀÔÑ â òåìå ÀÔÑ.

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •